Prehypertension and the cardiometabolic syndrome: Pathological and clinical consequences

Expert Review of Cardiovascular Therapy

Volumn 11, Issue 12, 2013, Pages 1725-1733

  Duprez, Daniel ^a   Toleuova, Aigerim ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Abdominal obesity; Cardiovascular disease; Dyslipidemia; Metabolic syndrome; Prediabetes; Prehypertension

Indexed keywords

AMILORIDE; ATORVASTATIN; CANDESARTAN; CHLORTALIDONE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDAPAMIDE; NIFEDIPINE; PLACEBO; RAMIPRIL; RESERPINE; TELMISARTAN; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; CARDIOMETABOLIC SYNDROME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIET; DIET RESTRICTION; DISEASE COURSE; DYSLIPIDEMIA; ELEVATED BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; HEART RATE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; PREHYPERTENSION; REVIEW; RISK ASSESSMENT; SALT INTAKE; SODIUM RETENTION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; HUMANS; HYPERTENSION; LIFE STYLE; METABOLIC SYNDROME X; PREHYPERTENSION; RISK FACTORS;

EID: 84888063292     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2013.857272     Document Type: Review

References (75)

1. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289, 2560-2572 (2003).
2. Mancia G, De Backer G, Dominiczak A et al. ESH-ESC practice guidelines for the management of arterial hypertension: esh-esc task force on the management of arterial hypertension. J. Hypertens 25, 1751-1762 (2007).
3. Pimenta E, Oparil S. Prehypertension: epidemiology, consequences and treatment. Nat. Rev. Nephrol. 6, 21-30 (2010).
4. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903-1913 (2002).
5. Vasan RS, Larson MG, Leip EP et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N. Engl. J. Med. 345, 1291-1297 (2001).
6. Guo X, Zhang X, Zheng L et al. Prehypertension is not associated with all-cause mortality: a systematic review and meta-analysis of prospective studies. PLoS ONE 8, e61796 (2013).
7. Murakami Y, Hozawa A, Okamura T, Ueshima H. Evidence for cardiovascular prevention from observational cohorts in Japan research group (EPOCH-JAPAN). relation of blood pressure and all-cause mortality in 180,000 Japanese participants: pooled analysis of 13 cohort studies. Hypertension 51, 1483-1491 (2008).
8. Reaven GM. Banting lecture. role of insulin resistance in human disease. Diabetes 37, 1595-1607 (1988).
9. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. a consensus statement from the international diabetes federation. Diabet. Med. 23, 469-480 (2006).
10. Alberti KGMM, Zimmet P. Definition, diagnosis, and classification of diabetes mellitus and its complications. WHO, Geneva, Switzerland, 32-33 (1999).
11. Beck-Nielsen H. General Characteristics of the insulin resistance syndrome: prevalence and heritability. European group for the study of insulin resistance (EGIR). Drugs 58 (Suppl. 1), 7-10, discussion 75-82 (1999).
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285, 2486-2497 (2001).
13. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109, 433-438 (2004).
14. Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch. Intern. Med. 165, 2644-2650 (2005).
15. Gami AS, Witt BJ, Howard DE. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol. 49, 403-414 (2007).
16. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 120, 1640-1645 (2009).
17. Eckel RH, Alberti KGMM, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 375, 181-183 (2010).
18. Asia Pacific Cohort Studies Collaboration. The burden of overweight and obesity in the Asia-Pacific region. Obes. Rev. 8, 191-196 (2007).
19. Alberti KGMM, Zimmet P, Shawb J. For the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 366, 157-163 (2005).
20. Ostchega Y, Yoon SS, Hughes J, Louis T. Hypertension awareness, treatment, and control-continued disparities in adults: United States, 2005-2006. NCHS Data Brief 3, 1-8 (2008).
21. Hsia J, Margolis KL, Eaton CB et al. Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation 115, 855-860 (2007).
22. Glasser SP, Judd S, Basile J, Lackland D et al. Prehypertension, racial prevalence and association with risk factors: analysis of the reasons for geographic and racial differences in stroke (REGARDS) study. Am. J. Hypertens. 24, 194-199 (2011).
23. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat. Report 5, 1-7 (2009).
24. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U. S. Diabetes Care 28, 2745-2749 (2005).
25. Weiss R, Bremer AA, Lustig RH. What is metabolic syndrome, and why are children getting it? Ann. N Y Acad. Sci. 1281, 123-140 (2013).
26. Sumner AD, Sardi GL, Reed JF 3rd. Components of the metabolic syndrome differ between young and old adults in the US population. J. Clin. Hypertens. (Greenwich). 14, 502-506 (2012).
27. Koebnick C. Smith N, Huang K, Martinez MP, Clancy HA, Kushi LH. The prevalence of obesity and obesity-related health conditions in a large, multiethnic cohort of young adults in California. Ann. Epidemiol. 22, 609-616 (2012).
28. Giannotti G, Doerries C, Mocharla PS et al. Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: relation to endothelial dysfunction. Hypertension 55, 1389-1397 (2010).
29. Taddei S, Virdis A. Mattei P, Ghiadoni L, Sudano I, Salvetti A. Defective L-argininenitric oxide pathway in offspring of essential hypertensive patients. Circulation 94, 1298-1303 (1996).
30. Peralta CA, Adeney KL, Shlipak MG et al. Structural and functional vascular alterations and incident hypertension in normotensive adults: the Multi-Ethnic study of atherosclerosis. Am. J. Epidemiol. 171, 63-71 (2010).
31. Duprez DA, Cohn JN. Monitoring vascular health beyond blood pressure. Curr. Hypertens. Rep. 8, 287-291 (2006).
32. Julius S. Tachycardia in hypertension: a saga of progress despite prejudice, confusion, and inertia. Prog. Cardiovasc. Dis. 52, 26-30 (2009).
33. Julius S, Krause L, Schork NJ et al. Hyperkinetic borderline hypertension in Tecumseh, Michigan. J. Hypertension. 9, 77-84 (1991).
34. Palatini P, Benetos A, Julius S. Impact of increased heart rate on clinical outcomes in hypertension. Drugs 66, 133-144 (2006).
35. Zhang Y, Lee ET, Devereux RB et al. Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: the strong heart study. Hypertension. 47, 410-414 (2006).
36. Player MS, Mainous 3rd AG, Diaz VA, Everett CJ. Prehypertension and insulin resistance in a nationally representative adult population. J. Clin. Hypertens. (Greenwich) 9, 424-429 (2007).
37. Rosenquist KJ, Pedley A, Massaro JM et al. Visceral and subcutaneous fat quality and cardiometabolic risk. JACC. Cardiovasc Imag. 6, 762-771(2013).
38. Putnam K, Shoemaker R, Yiannikouris F, Cassis LA. The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am. J. Physiol. Heart Circ. Physiol. 302, H1219-H1230 (2012).
39. Duprez DA. Aldosterone and the vasculature: mechanisms mediating resistant hypertension. J. Clin. Hypertens. (Greenwich) 9 (1 Suppl. 1), 13-18 (2007).
40. Vaidya A, Underwood PC, Hopkins PN et al. Abnormal aldosterone physiology and cardiometabolic risk factors. Hypertension 61, 886-893 (2013).
41. Hotamisligil GS. Inflammation and metabolic disorders. Nature 444, 860-867 (2006).
42. Shoelson, SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J. Clin. Invest.116, 1793-1801 (2006).
43. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes. 56, 1010-1013 (2007).
44. Romeo GR, Lee J, Shoelson SE. Metabolic syndrome, insulin resistance, and roles of inflammation-mechanisms and therapeutic targets. Arterioscler. Thromb. Vasc. Biol. 32, 1771-1776 (2012).
45. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med. 352, 48-62 (2005).
46. Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: a cardiometabolic risk in obesity and metabolic syndrome. J. Am. Coll. Cardiol. 62, 569-576 (2013).
47. Jialal I, Devaraj S, Singh U, Huet BA. Decreased number and impaired functionality of endothelial progenitor cells in subjects with metabolic syndrome: implications for increased cardiovascular risk. Atherosclerosis 211, 297-302 (2010).
48. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 35, 2402-2411 (2012).
49. Grundy SM, Hansen B, Smith SC Jr., Cleerman JI, Kahn RA. American heart association; national heart, lung, and blood institute. clinical management of metabolic syndrome: report of the american heart association/national, heart, lung, and blood institute/american diabetes association conference on scientific issues related to management. Circulation 109, 551-556 (2004).
50. Rocchini AP, Key J, Bondie D et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N. Engl. J. Med. 321,580-585 (1989).
51. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwel M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N. Engl. J. Med. 304, 930-933 (1981).
52. Engeli S, Böhnke J, Gorzelniak K et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 45, 356-362 (2005).
53. Appel LJ, Moore TJ, Obarzanek E et al. The effect of dietary patterns on blood pressure: results from the dietary approaches to stop hypertension trial. N. Engl. J. Med. 336, 1117-1124 (1997).
54. Elmer PJ, Obarzanek E, Vollmer WM et al. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann. Intern. Med. 144, 485-495 (2006).
55. Appel LJ, Sachs FM, Carey VJ et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the Omni Heart randomized trial. JAMA 294, 2455-2464 (2005).
56. Cook NR, Cutler JA, Obarzanek E et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 334, 885-888 (2007).
57. Appel LJ, Brands MW, Daniels SR et al. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension 47, 296-308 (2006).
58. Lien LF, Brown AJ, Ard JD et al. Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome. Hypertension 50, 609-616 (2007).
59. Estruch R, Ros E, Salas-Salvadó J et al. Primary prevention of cardiovascular disease with a mediterranean diet. N. Engl. J. Med. 368, 1279-1290 (2013).
60. Julius S, Nesbitt SD, Egan BM et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N. Engl. J. Med. 354, 1685-1697 (2006).
61. Lüders S, Schrader J, Berger J et al. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure - a prospective, randomized, controlled prevention trial of the German Hypertension League. J. Hypertens 26, 1487-1496 (2008).
62. Xue H, Zhang Y, Zhang H et al. Predictive factors of hypertension in high-normal blood pressure individuals-update from Chinom Study. J. Hypertens. 29, e19 (2011).
63. Fuchs FD, Fuchs SC, Moreira LB et al. Prevention of hypertension in patients with pre-hypertension: protocol for the PREVER-prevention trial. Trials 12, 65 (2011).
64. Sasamura H, Nakaya H, Julius S et al. The short treatment with the angiotensin receptor blocker candesartan surveyed by telemedicine (STAR CAST) study: rationale and study design. Hypertens. Res. 31, 1843-1849 (2008).
65. Grundy, S.M. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J. Am. Coll. Cardiol. 59, 635-643 (2012).
66. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 380, 565-571 (2012).
67. Wang KL, Liu CJ, Chao TF et al. Statins, risk of diabetes, and implications on outcomes in the general population. J. Am. Coll. Cardiol. 60, 1231-1238 (2012).
68. Culver AL, Ockene IS, Balasubramanian R et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch. Intern. Med. 23, 144-452 (2012).
69. Waters DD, Ho JE, Boekholdt SM et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J. Am. Coll. Cardiol. 61,148-152 (2013).
70. Taylor AJ, Villines TC, Stanek EJ. Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe. Eur. Heart J. 33, 2939-2945 (2012).
71. Cohn JN, Duprez DA. Time to foster a rational approach to preventing cardiovascular morbid events. J. Am. Coll. Cardiol. 52, 327-329 (2008).
72. Duprez DA, Florea N, Zhong W et al. Vascular and cardiac functional and structural screening to identify risk of future morbid events: preliminary observations. J. Am. Soc. Hypertens. 5, 401-409 (2011).
73. Saul SM, Duprez DA, Zhong W, Grandits GA, Cohn JN. Effect of carvedilol, lisinopril and their combination on vascular and cardiac health in patients with borderline blood pressure: the DETECT Study. J. Hum. Hypertens. 27, 362-367 (2013).
74. Duprez DA, Florea ND, Jones K, Cohn JN. Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study. J. Am. Coll. Cardiol. 50, 835-839 (2007).
75. Morse SA, Gulati R, Reisin E. The obesity paradox and cardiovascular disease. Curr. Hypertens. Rep. 12, 120-126 (2010).